Research ExplorerResearch projectsAdrecizumab in Cardiogenic Shock Publications

Adrecizumab in Cardiogenic Shock

Project: Research

1 - 1 out of 1Page size: 50

Publications

  1. 2022

  2. Single-dose of adrecizumab versus placebo in acute cardiogenic shock (ACCOST-HH): an investigator-initiated, randomised, double-blinded, placebo-controlled, multicentre trial

    Karakas, M., Akin, I., Burdelski, C., Clemmensen, P., Grahn, H., Jarczak, D., Keßler, M., Kirchhof, P., Landmesser, U., Lezius, S., Lindner, D., Mebazaa, A., Nierhaus, A., Ocak, A., Rottbauer, W., Sinning, C., Skurk, C., Söffker, G., Westermann, D., Zapf, A., Zengin, E., Zeller, T. & Kluge, S., 03.2022, In: LANCET RESP MED. 10, 3, p. 247-254 8 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review